Skip to main content
TipRanks
Go Ultimate75% OFF

Jenoptik (JEN) Q3 2026 Earnings Report

63 Followers

DE:JEN Q3 2026 EPS Results

Actual EPS
EUR 0.68
Consensus EPS
EUR 0.54
Beat/Miss
Beat by +EUR 0.14
One Year Ago EPS
EUR 0.37

DE:JEN Q3 2026 Revenue Results

Actual Revenue
EUR 300.60M
Expected Revenue
EUR 292.43M
Beat/Miss
Beat by +EUR 8.17M
YoY Revenue Growth
+17.97%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/10/2026
Time
TBA
Conference Call
Tuesday, November 10, 2026
DE:JEN Upcoming Earnings

Jenoptik's next earnings date is estimated for March 31, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 10, 2026|% Change Since:-14.69%|
Earnings Call Sentiment|Positive

The call was predominantly positive, supported by order intake growth of more than 40%, an order backlog above EUR 900 million, accelerating revenue, strong EBITDA and EPS growth, improved leverage, and upgraded EBITDA margin guidance. The main challenges were weak automotive markets, the HOMMEL impairment, working-capital needs, Q4 volatility, higher functional costs, and the temporary nature of the exceptionally high Q3 Semi margin.

Company Guidance

For full year 2026, Jenoptik reiterated revenue guidance of 5% to 9% growth and now expects EBITDA margin to be around 22%, compared with the previous expectation of between 20% to 21%; CapEx is expected to end the year on a lower level than 2025, while the working capital ratio is expected to trend to slightly above '25 levels. The company expects about 30% to 35% of the order book to be translated into sales for this year, with the vast, vast majority of the remaining order book translated into revenue in 2027; the Jena expansion is targeted to go live towards the end of next year, 2027, while CapEx guidance towards 2027 is too early. Semi revenue is expected to continue broadly in line with Q3 from a top-line point of view in the going quarters, but the Q3 margin should not be extrapolated; Biophotonics is expected to end the year with some moderate growth, OpEx is expected to be in line with inflation for Q4 and next year, and the company sees strong demand in 2027 and beyond, with no signals that this is going to change in the timeframe of '27, '28, while remaining positive for '29 and '30.

  • Strong Order Intake MomentumGroup order intake increased by more than 40% year-on-year in the first 9 months, exceeding expectations. OEM demand remained particularly strong, with the Semi ramp-up continuing and Biophotonics order intake growing from a very high prior-year base.
  • Robust Semi and Biophotonics DemandSemi & Advanced Manufacturing order intake in Q3 exceeded the already high levels of the first half, driven by lithography and continued strong customer activity in semi-inspection. Biophotonics order intake increased by around 11% year-on-year, mainly driven by medtech and life science.
  • Expanded Backlog and Book-to-BillThe group book-to-bill ratio rose sharply to around 1.4 at the 9-month stage, while the order backlog expanded to slightly above EUR 900 million.
  • Accelerating Revenue GrowthQ3 revenue grew by around 18% year-on-year, bringing first-nine-month revenue growth to almost 7%, or close to 8% excluding minor currency effects.
  • Strong Segment Revenue PerformanceSemi & Advanced Manufacturing revenue increased by almost 17% year-on-year, supported by lithography and semi-inspection. Smart Mobility Solutions revenue increased by almost 12%, driven by almost all regions.
  • Significant EBITDA ImprovementGroup EBITDA reached around EUR 178 million, up by a little more than 35% year-on-year. The EBITDA margin improved by around 470 basis points, driven by revenue growth and better fixed-cost absorption, the lower cost base from the prior-year cost-reduction program, and a stronger Semi product mix.
  • Very Strong Q3 ProfitabilityGroup EBITDA margin exceeded 26% in Q3. Management attributed the exceptionally strong quarterly product mix primarily to the Semi business, while noting that the Q3 margin should not be extrapolated into upcoming quarters.
  • Solid Segment MarginsSemi recorded an EBITDA margin close to 34% for the first 9 months, while Biophotonics maintained a strong margin of around 23% despite a revenue decline. Smart Mobility Solutions also improved margins as top-line growth generated operational leverage, and MPS returned to profitability at the 9-month stage.
  • Strong EBIT and EPS GrowthEBIT increased by almost 59% year-on-year, with the EBIT margin reaching 14.4%. Earnings per share increased by 60% to EUR 1.28.
  • Improved Financial PositionFree cash flow increased year-on-year, supported by lower investing cash outflows compared with the prior year, which included considerable cash outflows for new fab investments. Leverage improved to 1.1x from 1.6x at the end of the prior year.
  • Raised Full-Year EBITDA Margin GuidanceFull-year 2026 EBITDA margin guidance was increased to around 22%, compared with the previous expectation of between 20% and 21%. Revenue guidance was reiterated at 5% to 9% growth.
  • Capacity Expansion and Output FocusManagement is prioritizing higher output to serve the significantly increased backlog and is executing capacity expansion projects in its OEM businesses. The Jena site expansion for high-precision optical components and clean-room production is still targeted to go live toward the end of 2027.
  • Capacity Not Expected to Hinder 2027 GrowthManagement stated that capacity expansion is not expected to be a hurdle for growth next year, citing prior investment in the Dresden facility and the ability to increase capacity by adding machinery to existing production floors.
  • Positive Longer-Term Semiconductor OutlookManagement reported improving visibility compared with last year and the first half of 2026. Customer discussions indicate strong demand for major semiconductor equipment customers in lithography and inspection in 2027 and beyond, with no signals of a change in 2027 or 2028 and a positive view extending into 2029 and 2030.
  • Supply Chain and Ramp-Up ReadinessAlthough supply-chain constraints affect the industry, management said Jenoptik is in a good position to manage them. Programs are focused on machinery investments, adding labor, and establishing a supply chain capable of supporting the ramp, and management said the company can currently support customer growth requirements.
  • Continued Defense DemandDefense demand for infrared cameras and laser rangefinders remained very strong, and management expects the favorable defense mix in Biophotonics to continue in the upcoming period.
  • Datacom Business ProgressDigital datacom revenue was described as being in the low double-digit euro range. Management characterized the business as potentially interesting in terms of growth rates, while noting that it is not expected to reach the magnitude of the equipment business.
  • Capital Allocation Framework MaintainedManagement reiterated a capital allocation framework focused first on organic growth and expanding ramping businesses, followed by stable dividends in a stable environment and potential bolt-on acquisitions.
  • Upcoming Strategy UpdateThe company plans to host a Capital Markets Day on December 3 to present the results of its strategy review and provide further information on strategic direction and capital allocation.
  • Improving Prodomax OperationsManagement described Prodomax as having a fairly good Q3 after improvement in Q1 and Q2 and characterized the operational outlook as cautiously positive.

DE:JEN Earnings History

DE:JEN earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 31, 20272026 (Q4)0.59-0.51――
Nov 10, 20262026 (Q3)0.540.680.3782.70% (+0.31)
Aug 12, 20262026 (Q2)0.410.400.2653.85% (+0.14)
May 12, 20262026 (Q1)0.230.290.1773.65% (+0.12)
Mar 25, 20262025 (Q4)0.500.510.4414.77% (+0.07)
Nov 12, 20252025 (Q3)0.360.370.46-19.57% (-0.09)
Aug 13, 20252025 (Q2)0.290.260.42-38.10% (-0.16)
May 13, 20252025 (Q1)0.220.170.27-38.15% (-0.10)
Mar 25, 20252024 (Q4)0.420.440.3333.33% (+0.11)
Nov 12, 20242024 (Q3)0.420.460.3821.05% (+0.08)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed